Connect with Cryoport

Subscribe by Email

Your email:

Cryoport News and Events

Current Articles | RSS Feed RSS Feed

Cryoport Provides Logistics Solution and Services for Kite Pharma’s Lead Clinical Program in Cancer Immunotherapy

  
  
  

Lake Forest, CA, February 24, 2015 - Cryoport, Inc. (OTCBB: CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced that the Company’s best-in-class logistics solution is supporting Kite Pharma’s (“Kite”) clinical program for their lead product candidate, KTE-C19, a CAR-T cell therapy for non-Hodgkin’s lymphoma (“NHL”).

Cryoport and Sanaria Expand Logistics Partnership Supporting Malaria Vaccines

  
  
  

Lake Forest, CA, February 23, 2015 - Cryoport, Inc. (OTCBB: CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced that the Company is enhancing its cryogenic logistics support of its Sanaria partnership, which includes Sanaria’s production of malaria vaccine as well as its research and development efforts.

Cryoport Launches New Logistics Service Supporting Facility Relocation of Cryogenically Frozen Sample Collections

  
  
  

Lake Forest, CA, February 17, 2015 - Cryoport, Inc. (OTCBB: CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced the launch of a new logistics service supporting complete facility relocation of critical cryogenically frozen sample collections.

Cryoport Initiates Support of the Growing In-Vitro Fertilization Market in Nepal

  
  
  

Lake Forest, CA, February 10, 2015 - Cryoport, Inc. (OTCBB: CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for life sciences serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, and reproductive medicine, today announced it has initiated support of the growing in-vitro fertilization (“IVF”) market in Nepal.

Cryoport Reports Record Results; Grows Revenue by 50% for the First Nine Months of Fiscal 2015

  
  
  

LAKE FOREST, CA – February 5, 2015 — Cryoport, Inc. (CYRX) today announced financial results for its fiscal third quarter and nine months ended December 31, 2014.

Cryoport to Report Financial Results for Fiscal Third Quarter of 2015 and Provide Business Update on Thursday, February 5th

  
  
  

Lake Forest, CA, January 29, 2015 - Cryoport, Inc. (OTCBB:CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for life sciences serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, and reproductive medicine, today announced it will release its financial results for the fiscal third quarter ended December 31, 2014 on Thursday, February 5th.  

Cryoport Expands Sales Force To Address Growing Life Sciences Industry Demand

  
  
  

Lake Forest, CA, January 26, 2015 - Cryoport, Inc. (OTCBB: CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for life sciences serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, and reproductive medicine, today announced the expansion and restructuring of its national sales force in the United States.

Cryoport Appoints Mark W. Sawicki as Chief Commercial Officer to Lead Sales and Marketing Team

  
  
  

Lake Forest, CA, January 20, 2015 - Cryoport, Inc. (OTCBB: CYRX) ( “Company”), the leading provider of advanced cryogenic logistics solutions for life sciences serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced the appointment of Mark W. Sawicki, Ph.D. as Chief Commercial Officer of Cryoport Systems.

Cryoport Appoints Richard J. Berman to its Board of Directors

  
  
  

Lake Forest, CA, January 12, 2015 - Cryoport, Inc. (OTC BB:CYRX) (“Company”), the leading provider of advanced  cryogenic logistics solutions for life sciences serving markets including immunotherapies, stem cells, cell lines, contract research organizations , vaccine manufacturers, and IVF, today announced the appointment of Richard J. Berman to its Board of Directors. Mr. Berman will also serve as Chairman of the Audit Committee and Compensation Committee.

Cryoport Designated as Exclusive Cryogenic Logistics Provider to Triangle Research Labs

  
  
  

Lake Forest, CA, December 29, 2014 - Cryoport, Inc. (OTC BB: CYRX) ("the Company"), the leading provider of advanced cryogenic logistics solutions for life sciences, announced today that it has entered into an agreement with Triangle Research Labs, LLC (“TRL”).  Under the agreement, Cryoport becomes the exclusive cryogenic logistics provider for TRL, providing it with the ability to support its overall demand growth and meet its ever-increasing demand for same day cryogenic shipping.

All Posts